CODA Biotherapeutics Announces Preclinical Data From Epilepsy Program to be Presented at American Society of Gene & Cell Therapy 25th Annual Meeting

Research details assessment and selection of AAV regulatory cassettes that drive optimal expression of Company's novel engineered ligand-gated ion channel for the treatment of focal epilepsy Findings inform selection process of final development candidate SOUTH SAN FRANCISCO, Calif., May...

Click to view original post